Saad Z. Usmani, MD, FACP, Levine Cancer Institute
Articles
Third and Subsequent Line Options for Multiple Myeloma
Ajai Chari, MD, Mount Sinai Hospital;Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center;Saad Z. Usmani, MD, FACP, Levine Cancer Institute;Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021Read More
Updates in Multiple Myeloma in the Frontline Setting
Ajai Chari, MD, Mount Sinai Hospital;Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center;Saad Z. Usmani, MD, FACP, Levine Cancer Institute;Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021Read More
Latest Updated Articles
Published: May 27th 2024 | Updated: September 13th 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: September 17th 2024 | Updated: September 20th 2024
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
